| scholarly article | Q13442814 |
| P2093 | author name string | Yolanda Almaden | |
| Victoria Shalhoub | |||
| Francisco Javier Mendoza | |||
| Mariano Rodriguez | |||
| Antonio Canalejo | |||
| Julio Manuel Martinez-Moreno | |||
| Jose C. Estepa | |||
| Juan Rafael Munoz-Castaneda | |||
| M. Encarnacion Rodriguez-Ortiz | |||
| Rocío Canalejo | |||
| P2860 | cites work | Cloning and characterization of FGF23 as a causative factor of tumor-induced osteomalacia | Q24623628 |
| Single-Step Method of RNA Isolation by Acid Guanidinium Thiocyanate–Phenol–Chloroform Extraction | Q25938986 | ||
| Klotho converts canonical FGF receptor into a specific receptor for FGF23 | Q28272505 | ||
| alpha-Klotho as a regulator of calcium homeostasis | Q28306317 | ||
| The parathyroid is a target organ for FGF23 in rats | Q28572613 | ||
| Circulating FGF-23 is regulated by 1alpha,25-dihydroxyvitamin D3 and phosphorus in vivo | Q28572995 | ||
| Regulation of fibroblast growth factor-23 signaling by klotho | Q28587100 | ||
| Fibroblast growth factor 23 and mortality among patients undergoing hemodialysis | Q33932297 | ||
| Circulating concentration of FGF-23 increases as renal function declines in patients with chronic kidney disease, but does not change in response to variation in phosphate intake in healthy volunteers | Q33974129 | ||
| Fibroblast growth factor-23 mitigates hyperphosphatemia but accentuates calcitriol deficiency in chronic kidney disease | Q34557934 | ||
| FGFR3 and FGFR4 do not mediate renal effects of FGF23. | Q36985772 | ||
| Phosphorus restriction prevents parathyroid gland growth. High phosphorus directly stimulates PTH secretion in vitro | Q37355688 | ||
| Detergent and proteolytic enzyme-based techniques for nuclear isolation and DNA content analysis. | Q40397799 | ||
| Serum fibroblast growth factor-23 levels predict the future refractory hyperparathyroidism in dialysis patients. | Q40447584 | ||
| Regulation of parathyroid vitamin D receptor expression by extracellular calcium. | Q44223967 | ||
| Direct upregulation of parathyroid calcium-sensing receptor and vitamin D receptor by calcimimetics in uremic rats | Q46192901 | ||
| Sevelamer hydrochloride and calcium bicarbonate reduce serum fibroblast growth factor 23 levels in dialysis patients | Q46631801 | ||
| Fibroblast growth factor-23 regulates parathyroid hormone and 1alpha-hydroxylase expression in cultured bovine parathyroid cells | Q46970328 | ||
| Severely reduced production of klotho in human chronic renal failure kidney | Q49064415 | ||
| Decreased calcium-sensing receptor expression in hyperplastic parathyroid glands of uremic rats: role of dietary phosphate | Q50109526 | ||
| Diminished parathyroid 1,25(OH)2D3 receptors in experimental uremia | Q69810060 | ||
| Direct effect of phosphorus on PTH secretion from whole rat parathyroid glands in vitro | Q71512074 | ||
| Abnormal expression and regulation of vitamin D receptor in experimental uremia | Q71653471 | ||
| High phosphate level directly stimulates parathyroid hormone secretion and synthesis by human parathyroid tissue in vitro | Q77417313 | ||
| Type I membrane klotho expression is decreased and inversely correlated to serum calcium in primary hyperparathyroidism | Q81746919 | ||
| P433 | issue | 7 | |
| P304 | page(s) | 1125–1135 | |
| P577 | publication date | 2010-07-01 | |
| P1433 | published in | Journal of the American Society of Nephrology | Q17123893 |
| P1476 | title | FGF23 fails to inhibit uremic parathyroid glands | |
| P478 | volume | 21 |
| Q38544533 | Advances in pharmacotherapy for secondary hyperparathyroidism |
| Q36177303 | Arterial calcification and bone physiology: role of the bone-vascular axis |
| Q47989110 | Biology of Fibroblast Growth Factor 23: From Physiology to Pathology |
| Q48038085 | Calcium Homeostasis in Health and in Kidney Disease |
| Q36050923 | Calcium deficiency reduces circulating levels of FGF23. |
| Q26863412 | Calcium regulation and bone mineral metabolism in elderly patients with chronic kidney disease |
| Q27024043 | Cardiovascular Risk Factors and Chronic Kidney Disease-FGF23: A Key Molecule in the Cardiovascular Disease |
| Q92533944 | Chronic Kidney Disease-Mineral and Bone Disorder (CKD-MBD): Current Perspectives |
| Q37993874 | Cinacalcet: will it play a role in reducing cardiovascular events? |
| Q58787885 | Correlation between Soluble -Klotho and Renal Function in Patients with Chronic Kidney Disease: A Review and Meta-Analysis |
| Q47750453 | Coupling between phosphate and calcium homeostasis: a mathematical model |
| Q50538825 | Direct and indirect effects of parathyroid hormone on circulating levels of fibroblast growth factor 23 in vivo. |
| Q35138667 | Direct, acute effects of Klotho and FGF23 on vascular smooth muscle and endothelium |
| Q37912038 | Diseases of the parathyroid gland in chronic kidney disease. |
| Q37801814 | Disorders of phosphorus homeostasis |
| Q37891153 | Does it matter how parathyroid hormone levels are suppressed in secondary hyperparathyroidism? |
| Q35682152 | Effect of Cinacalcet and Vitamin D Analogs on Fibroblast Growth Factor-23 during the Treatment of Secondary Hyperparathyroidism |
| Q34571776 | Elevated FGF23 levels are associated with impaired calcium-mediated suppression of PTH in ESRD. |
| Q38123396 | FGF-23 and secondary hyperparathyroidism in chronic kidney disease |
| Q37996937 | FGF23 and PTH--double agents at the heart of CKD. |
| Q36639867 | FGF23 production by osteocytes |
| Q64063902 | FGF23, Biomarker or Target? |
| Q48141632 | Fibroblast Growth Factor (FGF) 23 Regulates the Plasma Levels of Parathyroid Hormone In Vivo Through the FGF Receptor in Normocalcemia, But Not in Hypocalcemia. |
| Q26866263 | Fibroblast Growth Factor 23: A New Dimension to Diseases of Calcium-Phosphorus Metabolism |
| Q30544587 | Fibroblast growth factor 23 and Klotho: physiology and pathophysiology of an endocrine network of mineral metabolism |
| Q51199021 | Fibroblast growth factor 23 and soluble klotho in children with chronic kidney disease. |
| Q35099518 | Fibroblast growth factor 23 is elevated before parathyroid hormone and phosphate in chronic kidney disease |
| Q38072361 | Fibroblast growth factor 23: associations with cardiovascular disease and mortality in chronic kidney disease |
| Q41907618 | Functional heterogeneity of osteocytes in FGF23 production: the possible involvement of DMP1 as a direct negative regulator. |
| Q35077013 | High dose intravenous iron, mineral homeostasis and intact FGF23 in normal and uremic rats |
| Q37446664 | Increasing dietary phosphorus intake from food additives: potential for negative impact on bone health |
| Q37851395 | Is fibroblast growth factor 23 a harbinger of mortality in CKD? |
| Q85670159 | Key role of the kidney in the regulation of fibroblast growth factor 23 |
| Q38104935 | Klotho and chronic kidney disease |
| Q36227410 | Longitudinal evaluation of FGF23 changes and mineral metabolism abnormalities in a mouse model of chronic kidney disease |
| Q48633678 | Low Dentin Matrix Protein 1 Is Associated With Incident Cardiovascular Events in Peritoneal Dialysis Patients. |
| Q37542842 | Magnesium modulates parathyroid hormone secretion and upregulates parathyroid receptor expression at moderately low calcium concentration |
| Q35059924 | Molecular regulation of phosphate metabolism by fibroblast growth factor-23-klotho system |
| Q64229493 | Not all forms of dietary phosphorus are equal: an evaluation of postprandial phosphorus concentrations in the plasma of the cat |
| Q35059741 | Osteo-renal regulation of systemic phosphate metabolism |
| Q41911259 | Parathyroid diseases and animal models |
| Q46101921 | Parathyroid hormone activates the orphan nuclear receptor Nurr1 to induce FGF23 transcription |
| Q39823001 | Parathyroid resistance to FGF23 in kidney transplant recipients: back to the past or ahead to the future? |
| Q35069203 | Parathyroid-specific deletion of Klotho unravels a novel calcineurin-dependent FGF23 signaling pathway that regulates PTH secretion |
| Q35119033 | Parathyroid-specific epidermal growth factor-receptor inactivation prevents uremia-induced parathyroid hyperplasia in mice |
| Q38572880 | Pathophysiology of Calcium, Phosphorus, and Magnesium Dysregulation in Chronic Kidney Disease. |
| Q41834884 | Persistent fibroblast growth factor 23 signalling in the parathyroid glands for secondary hyperparathyroidism in mice with chronic kidney disease |
| Q37807991 | Pharmacotherapy and interventional treatments for secondary hyperparathyroidism: current therapy and future challenges |
| Q58797979 | Phosphate control in reducing FGF23 levels in hemodialysis patients |
| Q39693940 | Phosphorylation of Ribosomal Protein S6 Mediates Mammalian Target of Rapamycin Complex 1-Induced Parathyroid Cell Proliferation in Secondary Hyperparathyroidism. |
| Q26777613 | Pre-treatment considerations in childhood hypertension due to chronic kidney disease |
| Q45059694 | Prevalence of intracranial artery calcification in hemodialysis patients--a case-control study |
| Q26860470 | Regulation and function of the FGF23/klotho endocrine pathways |
| Q36672616 | Renal and extrarenal actions of Klotho |
| Q37095085 | Renal phosphate handling: Physiology |
| Q55413395 | Role of etelcalcetide in the management of secondary hyperparathyroidism in hemodialysis patients: a review on current data and place in therapy. |
| Q39220825 | Secondary Hyperparthyroidism: Pathogenesis, Diagnosis, Preventive and Therapeutic Strategies. |
| Q37190542 | Secreted klotho and chronic kidney disease |
| Q58789309 | TGF-Beta Signaling in Bone with Chronic Kidney Disease |
| Q60921125 | The Emerging Role of Nutritional Vitamin D in Secondary Hyperparathyroidism in CKD |
| Q39515008 | The inflammatory cytokines TWEAK and TNFα reduce renal klotho expression through NFκB. |
| Q38020094 | The role of FGF23 in CKD--with or without Klotho. |
| Q38086910 | The role of phosphorus in the pathophysiology of chronic kidney disease. |
| Q38851700 | The role of vitamin K in vascular calcification of patients with chronic kidney disease |
| Q42233431 | Tradeoff-in-the-Nephron: A Theory to Explain the Primacy of Phosphate in the Pathogenesis of Secondary Hyperparathyroidism |
| Q36210285 | Update on fibroblast growth factor 23 in chronic kidney disease |
| Q36167508 | Validity of Klotho, CYR61 and YKL-40 as ideal predictive biomarkers for acute kidney injury: review study |
| Q34025119 | Vegetarian compared with meat dietary protein source and phosphorus homeostasis in chronic kidney disease |
| Q33703957 | Vitamin D prohormone in the treatment of secondary hyperparathyroidism in patients with chronic kidney disease |
| Q39812781 | αKlotho and Chronic Kidney Disease |
Search more.